Seventeen patient advocacy groups, including Consumers Union, the Cancer Prevention and Treatment Fund and the National Alliance for Hispanic Health have submitted a letter to the FDA expressing concern over a new HPV DNA test. The test, which would be recommended for women age 25 and older, is currently under FDA review. Opponents of the test cite its expense (much more than a Pap test) and the potential for confusion over screening recommendations, which may lead to over or under screening. Read more about the debate surrounding this HPV screening tool here: